Tianjin Chase Sun Pharmaceutical Co Ltd. Stock Analysis 300026.SZ

Tianjin Chase Sun Pharmaceutical Co., Ltd. engages in the research and development, production, and marketing of pharmaceutical products. The company is headquartered in Tianjin, Tianjin and currently employs 4,852 full-time employees. The company went IPO on 2009-10-30. The firm's main businesses include Chinese medicine formula granules, finished drugs, medical devices, raw materials and excipients, medical health services and smart supply chain of drugs and devices. The firm's finished drugs include Xuebijing Injection, low molecular weight heparin calcium injection, moxifloxacin hydrochloride sodium chloride injection, enoxaparin sodium injection and others. Medical device products are mainly electronic medical devices, including blood oxygen series, home health and primary care. The raw materials and excipients business focuses on the research and development and production of heparin sodium and low molecular weight heparin series raw materials. The firm conducts its businesses in the domestic and foreign markets.